MX2017003018A - Imitadores de mir-29 y usos de los mismos. - Google Patents
Imitadores de mir-29 y usos de los mismos.Info
- Publication number
- MX2017003018A MX2017003018A MX2017003018A MX2017003018A MX2017003018A MX 2017003018 A MX2017003018 A MX 2017003018A MX 2017003018 A MX2017003018 A MX 2017003018A MX 2017003018 A MX2017003018 A MX 2017003018A MX 2017003018 A MX2017003018 A MX 2017003018A
- Authority
- MX
- Mexico
- Prior art keywords
- mir
- mimetics
- present
- mimics
- oligonucleotide mimetics
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/343—Spatial arrangement of the modifications having patterns, e.g. ==--==--==--
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
- C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Dispersion Chemistry (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
Abstract
La invencion actual se refiere a imitadores de oligonucleotido sinteticos de ARNmi. En particular, la invencion actual proporciona imitadores de oligonucleotido quimicamente modificados, de hebra doble, de miR-29. Tambien se describen composiciones farmaceuticas que comprenden los imitadores y sus usos en el tratamiento o prevencion de afecciones asociadas con la desregulacion de los genes de matriz extracelular, tales como afecciones fibroticas del tejido.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462047562P | 2014-09-08 | 2014-09-08 | |
PCT/US2015/049018 WO2016040373A1 (en) | 2014-09-08 | 2015-09-08 | Mir-29 mimics and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2017003018A true MX2017003018A (es) | 2018-01-24 |
Family
ID=55436959
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017003018A MX2017003018A (es) | 2014-09-08 | 2015-09-08 | Imitadores de mir-29 y usos de los mismos. |
Country Status (14)
Country | Link |
---|---|
US (3) | US9376681B2 (es) |
EP (1) | EP3201213B1 (es) |
JP (1) | JP6837963B2 (es) |
KR (1) | KR20170068452A (es) |
CN (1) | CN107108685B (es) |
AU (1) | AU2015315298B2 (es) |
BR (1) | BR112017004648A2 (es) |
CA (1) | CA2960387A1 (es) |
CL (1) | CL2017000564A1 (es) |
IL (1) | IL250952A0 (es) |
MX (1) | MX2017003018A (es) |
PH (1) | PH12017500424A1 (es) |
RU (1) | RU2712511C2 (es) |
WO (1) | WO2016040373A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101883576B (zh) | 2007-07-31 | 2015-08-19 | 得克萨斯系统大学董事会 | 调控纤维化的微小rna家族及其用途 |
GB201400598D0 (en) | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
US9376681B2 (en) | 2014-09-08 | 2016-06-28 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
US10801025B2 (en) | 2016-07-26 | 2020-10-13 | Indiana University Research And Technology Corporation | MicroRNA therapy for pancreatic cancer |
EP4035659A1 (en) | 2016-11-29 | 2022-08-03 | PureTech LYT, Inc. | Exosomes for delivery of therapeutic agents |
CN107982536B (zh) * | 2017-10-27 | 2021-04-09 | 上海交通大学医学院附属第九人民医院 | 一种药物作用靶点的组合物和应用 |
US20200376019A1 (en) * | 2017-11-30 | 2020-12-03 | MiRagen Therapeutics, Inc. | miR29 MIMICS FOR THE TREATMENT OF OCULAR FIBROSIS |
US11021712B1 (en) | 2018-09-07 | 2021-06-01 | Washington University | MiRNA mimics and uses thereof |
CN109234381B (zh) * | 2018-10-22 | 2021-06-18 | 云南省玉溪市人民医院 | miR-2682-5p作为肾纤维化标志物的应用 |
WO2020181130A2 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Polynucleotide conjugates and uses thereof |
WO2020181107A1 (en) * | 2019-03-05 | 2020-09-10 | MiRagen Therapeutics, Inc. | Microrna mimics and uses thereof |
WO2020247610A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Mesenchymal stem cell-derived extracellular vesicles and uses thereof for treating and diagnosing fibrotic diseases |
WO2020247675A1 (en) * | 2019-06-06 | 2020-12-10 | Spiritus Therapeutics, Inc. | Methods for attenuating viral infection and for treating lung injury |
CN111249466B (zh) * | 2020-03-14 | 2022-04-15 | 浙江大学医学院附属第一医院 | 丹参酮ⅡA与miR-29b抑制剂联合在制备治疗肌腱粘连的药物中的应用 |
CN111449025A (zh) * | 2020-04-02 | 2020-07-28 | 华北理工大学 | miRNAs在抑制大鼠肝纤维化中的应用 |
US11987793B2 (en) | 2020-05-03 | 2024-05-21 | Washington University | Compositions and methods for prevention of bladder fibrosis |
CN111647656A (zh) * | 2020-05-15 | 2020-09-11 | 华中科技大学同济医学院附属同济医院 | mir-29a基因在检测肝癌及肝纤维化中的应用及所述基因条件敲入小鼠的构建方法 |
CN112226436B (zh) * | 2020-10-20 | 2021-05-18 | 南京医科大学 | MiR-29海绵、包含miR-29海绵的核酸构建体及其应用 |
GB202016863D0 (en) * | 2020-10-23 | 2020-12-09 | Causeway Therapeutics Ltd | Microrna-29 compounds, compositions and uses in therapy |
CN117813099A (zh) * | 2021-08-06 | 2024-04-02 | 领康冠军有限公司 | 基于miRNA的组合物及其使用方法 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981505A (en) | 1993-01-26 | 1999-11-09 | The Trustees Of The University Of Pennsylvania | Compositions and methods for delivery of genetic material |
AU7404994A (en) | 1993-07-30 | 1995-02-28 | Regents Of The University Of California, The | Endocardial infusion catheter |
US5837533A (en) | 1994-09-28 | 1998-11-17 | American Home Products Corporation | Complexes comprising a nucleic acid bound to a cationic polyamine having an endosome disruption agent |
US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
US6416510B1 (en) | 1997-03-13 | 2002-07-09 | Biocardia, Inc. | Drug delivery catheters that attach to tissue and methods for their use |
US6217900B1 (en) | 1997-04-30 | 2001-04-17 | American Home Products Corporation | Vesicular complexes and methods of making and using the same |
JP2002510319A (ja) | 1997-07-01 | 2002-04-02 | アイシス・ファーマシューティカルス・インコーポレーテッド | オリゴヌクレオチドの消化管を介したデリバリーのための組成物及び方法 |
US6749617B1 (en) | 1997-11-04 | 2004-06-15 | Scimed Life Systems, Inc. | Catheter and implants for the delivery of therapeutic agents to tissues |
US6716242B1 (en) | 1999-10-13 | 2004-04-06 | Peter A. Altman | Pulmonary vein stent and method for use |
US6693187B1 (en) | 2000-10-17 | 2004-02-17 | Lievre Cornu Llc | Phosphinoamidite carboxlates and analogs thereof in the synthesis of oligonucleotides having reduced internucleotide charge |
US7083642B2 (en) | 2000-12-22 | 2006-08-01 | Avantec Vascular Corporation | Delivery of therapeutic capable agents |
US7247313B2 (en) | 2001-06-27 | 2007-07-24 | Advanced Cardiovascular Systems, Inc. | Polyacrylates coatings for implantable medical devices |
US6589286B1 (en) | 2001-09-12 | 2003-07-08 | Jason Litner | Eustachian tube stent |
AU2002347035B2 (en) * | 2001-09-28 | 2008-04-03 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V | Micro-RNA molecules |
US7236821B2 (en) | 2002-02-19 | 2007-06-26 | Cardiac Pacemakers, Inc. | Chronically-implanted device for sensing and therapy |
WO2003093449A2 (en) | 2002-05-06 | 2003-11-13 | Nucleonics, Inc. | Methods for delivery of nucleic acids |
AU2003250913A1 (en) | 2002-07-08 | 2004-01-23 | Abbott Laboratories Vascular Enterprises Limited | Drug eluting stent and methods of manufacture |
US7294329B1 (en) | 2002-07-18 | 2007-11-13 | Advanced Cardiovascular Systems, Inc. | Poly(vinyl acetal) coatings for implantable medical devices |
US7232573B1 (en) | 2002-09-26 | 2007-06-19 | Advanced Cardiovascular Systems, Inc. | Stent coatings containing self-assembled monolayers |
US7087263B2 (en) | 2002-10-09 | 2006-08-08 | Advanced Cardiovascular Systems, Inc. | Rare limiting barriers for implantable medical devices |
US7144422B1 (en) | 2002-11-13 | 2006-12-05 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and methods of making the same |
US7105018B1 (en) | 2002-12-30 | 2006-09-12 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent cover and method of use |
US7156869B1 (en) | 2003-01-27 | 2007-01-02 | Advanced Cardiovascular Systems, Inc. | Drug-eluting stent and delivery system with tapered stent in shoulder region |
US7041127B2 (en) | 2003-05-28 | 2006-05-09 | Ledergerber Walter J | Textured and drug eluting coronary artery stent |
US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
US7055237B2 (en) | 2003-09-29 | 2006-06-06 | Medtronic Vascular, Inc. | Method of forming a drug eluting stent |
CA2557480A1 (en) | 2004-02-26 | 2005-09-09 | V-Kardia Pty Ltd | Isolating cardiac circulation |
US20070203445A1 (en) | 2004-02-26 | 2007-08-30 | V-Kardia Pty Ltd | Isolating cardiac circulation |
US7722596B2 (en) | 2004-02-26 | 2010-05-25 | Osprey Medical, Inc. | Regional cardiac tissue treatment |
WO2006089340A2 (en) | 2005-02-23 | 2006-08-31 | V-Kardia Pty Ltd | Polynucleotide delivery to cardiac tissue |
US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
CA2622584C (en) | 2005-09-15 | 2015-08-11 | Novosom Ag | Improvements in or relating to amphoteric liposomes |
EP2388328A1 (en) | 2006-01-27 | 2011-11-23 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for the use in modulation of micrornas |
US20100184209A1 (en) * | 2006-02-17 | 2010-07-22 | Dharmacon, Inc. | Compositions and methods for inhibiting gene silencing by rna interference |
CA2663601C (en) * | 2006-09-22 | 2014-11-25 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by rna interference |
CN101883576B (zh) | 2007-07-31 | 2015-08-19 | 得克萨斯系统大学董事会 | 调控纤维化的微小rna家族及其用途 |
US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
EP2096171A1 (en) * | 2008-02-27 | 2009-09-02 | Julius-Maximilians-Universität Würzburg | MicroRNA (miRNA) and down-stream targets for diagnostic and therapeutic purposes |
JP2012502007A (ja) | 2008-09-04 | 2012-01-26 | ウニベルシテート チューリッヒ プロレクトラート エムエヌヴェー | 強皮症の治療 |
WO2010039502A2 (en) | 2008-09-23 | 2010-04-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Micrornas in idiopathic pulmonary fibrosis |
EP2411520A2 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF THE THYMIC STROMAL LYMPHOPOIETIN (TSLP) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
WO2010129672A1 (en) * | 2009-05-05 | 2010-11-11 | Miragen Therapeutics | Lipophilic polynucleotide conjugates |
JP2011004708A (ja) * | 2009-06-29 | 2011-01-13 | Univ Of Tokyo | smallRNA二本鎖およびヘアピン型RNAの設計方法 |
WO2011028550A1 (en) | 2009-08-24 | 2011-03-10 | Merck Sharp & Dohme Corp. | Segmented micro rna mimetics |
EP2371370A1 (en) * | 2010-04-01 | 2011-10-05 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Antagonists of miRNA-29 expression and their use in the prevention and treatment of aortic aneurysms and atherosclerotic plaque destabilization |
US9914972B2 (en) * | 2011-03-28 | 2018-03-13 | Rosetta Genomics Ltd. | Methods for lung cancer classification |
AU2012242761A1 (en) * | 2011-04-12 | 2013-10-31 | Beth Israel Deaconess Medical Center, Inc. | Micro-RNA inhibitors and their uses in disease |
WO2013032962A2 (en) | 2011-08-28 | 2013-03-07 | The Board Of Trustees Of The Leland Stanford Junior University | Micro rnas to treat stroke, ischemic brain injury, traumatic brain injury, and neurodegenerative disease |
CN103987858A (zh) | 2011-11-22 | 2014-08-13 | 英特芒尼公司 | 诊断和治疗特发性肺纤维化的方法 |
GB201400598D0 (en) * | 2014-01-14 | 2014-03-05 | Univ Glasgow | Materials and methods for modulation of tendon healing |
US10150966B2 (en) | 2014-03-04 | 2018-12-11 | Hirofumi Yamamoto | RNA sequence having anti-tumour activity |
US9376681B2 (en) | 2014-09-08 | 2016-06-28 | MiRagen Therapeutics, Inc. | miR-29 mimics and uses thereof |
-
2015
- 2015-09-08 US US14/848,085 patent/US9376681B2/en active Active
- 2015-09-08 CN CN201580057333.0A patent/CN107108685B/zh not_active Expired - Fee Related
- 2015-09-08 AU AU2015315298A patent/AU2015315298B2/en not_active Ceased
- 2015-09-08 CA CA2960387A patent/CA2960387A1/en not_active Abandoned
- 2015-09-08 WO PCT/US2015/049018 patent/WO2016040373A1/en active Application Filing
- 2015-09-08 EP EP15840320.4A patent/EP3201213B1/en active Active
- 2015-09-08 KR KR1020177008019A patent/KR20170068452A/ko not_active Application Discontinuation
- 2015-09-08 JP JP2017513109A patent/JP6837963B2/ja active Active
- 2015-09-08 MX MX2017003018A patent/MX2017003018A/es unknown
- 2015-09-08 RU RU2017111775A patent/RU2712511C2/ru active
- 2015-09-08 BR BR112017004648A patent/BR112017004648A2/pt not_active Application Discontinuation
-
2016
- 2016-06-07 US US15/175,636 patent/US9994847B2/en not_active Expired - Fee Related
-
2017
- 2017-03-06 IL IL250952A patent/IL250952A0/en unknown
- 2017-03-07 PH PH12017500424A patent/PH12017500424A1/en unknown
- 2017-03-08 CL CL2017000564A patent/CL2017000564A1/es unknown
-
2018
- 2018-06-07 US US16/002,845 patent/US20190127734A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US9994847B2 (en) | 2018-06-12 |
US9376681B2 (en) | 2016-06-28 |
RU2017111775A3 (es) | 2019-03-14 |
KR20170068452A (ko) | 2017-06-19 |
US20160355815A1 (en) | 2016-12-08 |
CN107108685A (zh) | 2017-08-29 |
EP3201213B1 (en) | 2021-06-02 |
BR112017004648A2 (pt) | 2018-05-08 |
RU2017111775A (ru) | 2018-10-10 |
PH12017500424B1 (en) | 2017-07-17 |
IL250952A0 (en) | 2017-04-30 |
CA2960387A1 (en) | 2016-03-17 |
US20190127734A1 (en) | 2019-05-02 |
RU2712511C2 (ru) | 2020-01-29 |
WO2016040373A1 (en) | 2016-03-17 |
EP3201213A1 (en) | 2017-08-09 |
PH12017500424A1 (en) | 2017-07-17 |
CL2017000564A1 (es) | 2018-05-04 |
CN107108685B (zh) | 2020-10-20 |
EP3201213A4 (en) | 2018-07-25 |
US20160068842A1 (en) | 2016-03-10 |
JP2017527294A (ja) | 2017-09-21 |
AU2015315298B2 (en) | 2020-05-14 |
JP6837963B2 (ja) | 2021-03-03 |
AU2015315298A1 (en) | 2017-03-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12017500424B1 (en) | Mir-29 mimics and uses thereof | |
EP3326661B8 (en) | Bio-ink composition having improved physical and biological properties | |
MX2019009789A (es) | Metodos de seleccion para microorganismos que imparten propiedades beneficiosas a las plantas. | |
IL290633A (en) | 5'-cyclophosphonate modified nucleotides, preparations containing them and their uses | |
WO2016029191A3 (en) | Channel modulators | |
SG10201809290SA (en) | Compositions and Methods to Treating Hemoglobinopathies | |
MX2017002085A (es) | Tratamientos con nanopartículas núcleo-corteza de proteína/oligonucleótido. | |
MX2017001290A (es) | Composicion para el tratamiento de telas que comprende una nanoemulsion de polimero de aminosiloxano. | |
WO2015175977A3 (en) | Antisense antibacterial compounds and methods | |
AR102777A1 (es) | COMPOSICIONES DE ARNi CONTRA TMPRSS6 Y MÉTODOS PARA SU USO | |
MX2017008414A (es) | Composiciones inhibidoras de nitrificacion y metodos para preparar las mismas. | |
MA40460A (fr) | Ciblage lysosomial et utilisation correspondante | |
EP3607961A4 (en) | APPLICATION OF PLANT EXTRACTS IN THE PREPARATION OF A PHARMACEUTICAL COMPOSITION INTENDED TO INCREASE GENE EXPRESSION TGM1, KRT, AQP3, FLG, GBA AND HAS | |
TW201613949A (en) | Targeting microRNAs for metabolic disorders | |
EP3119781A4 (en) | Compounds which inhibit rna polymerase, compositions including such compounds, and their use | |
DK3282847T3 (en) | Selection and use of cold-tolerant Bacillus strains as biological phytostimulators | |
PE20150619A1 (es) | Moleculas de siarn que interfieren con la expresion del receptor vaniloide-1 (trpv1) | |
MX2015001648A (es) | Composiciones que comprenden derivados de espicamicina y metodos de uso de los mismos. | |
ZA201801302B (en) | Novel microorganisms and their use in agriculture | |
ZA201800633B (en) | Biodegradable antimicrobial compositions and uses thereof to combat microorganisms | |
MX368084B (es) | siRNA Y SU USO EN LA PREPARACIÓN DE UN MEDICAMENTO PARA USARSE EN UN MÉTODO PARA EL TRATAMIENTO DE UN TRANSTORNO OCULAR. | |
MX365952B (es) | Composiciones para la prevención y/o el tratamiento de patologías relacionadas con alfa-glucosidasa. | |
WO2015118407A3 (en) | Oligonucleotides and methods for inhibiting or reducing bacterial biofilms | |
MX2020006430A (es) | Oligonucleotidos que comprenden un enlace internucleosidico de fosforoditioato. | |
HK1257658A1 (zh) | Sirna及其在抑制nrarp基因表達的方法和組合物中的用途 |